Soleno Therapeutics. Every tracked FinTwit mention of $SLNO, newest first. 22 mentions since the first on Aug 21, 2025. See the price chart.
April 2026 · 1 mention
Apr 20
Adam Feuerstein ✡️ — @fakepharmabro $SLNO had very little leverage given Vykat's safety vulnerabilities. Shareholders are probably lucky that they're getting $53 per share.↗
February 2026 · 1 mention
Feb 25
Adam Feuerstein ✡️ — If you were wondering, is Scorpion still short $SLNO? Yup, he is.↗
January 2026 · 1 mention
Jan 12
Adam Feuerstein ✡️ — $SLNO preliminary Q4 Vykat sales $90-92M vs $86M Visible Alpha consensus.
That's somewhat of a relief.
Good #JPM26 Monday morning to you all!↗
November 2025 · 10 mentions
Nov 11
Adam Feuerstein ✡️ — $SLNO is repurchasing $100M of its stock. Strong move.
https://t.co/urev6a6Cqn↗
Nov 5
Adam Feuerstein ✡️ — $SLNO has a lot of work to do. Management has not handled this situation well at all. @ScorpionFund is right about the call last night. It was terrible. If Kir is wrong about Vykat…↗
Nov 4
Adam Feuerstein ✡️ — My unsolicited advice to $SLNO would be: More offense, less defense.
Q3 was good. $66M in sales, 397 new start forms (higher than Q2), discontinuation rate higher but within expe…↗
Nov 4
Adam Feuerstein ✡️ — @bigpharmaguy As a $SLNO shareholder, I wouldn't want Anish to be Doug Ingram, but maybe a little teeny bit sprinkled in?
October 2025 · 2 mentions
Oct 21
Adam Feuerstein ✡️ — @BiotechPort I didn't invent the expectation of $SLNO pre-announcing Q3 sales. I'm merely telling you 1/ it existed; and 2/ it's not happening.↗
Oct 21
Adam Feuerstein ✡️ — $SLNO did not preannounce Q3 sales. That's disappointing, as much as disclosure of preliminary Vykat XR sales for Q3 was a possibility to counter the bear thesis. Looks like we nee…↗
September 2025 · 5 mentions
Sep 25
Adam Feuerstein ✡️ — This week's Biotech scorecard newsletter: (Almost) 100% positive vibes
1. $QURE, of course.
The 75% slowing of disease progression reported by Uniqure with its Huntington’s dis…↗
Sep 24
Adam Feuerstein ✡️ — Acadia Pharma $ACAD drug for Prader-Willi syndrome fails late-stage study
In reaction, $SLNO higher
https://t.co/OLXtLcVBy5↗
Sep 24
Adam Feuerstein ✡️ — $ACAD ACAP-101 study in Prader-Willi failed to improve hyperphagia behavior. $SLNO↗
Sep 16
Adam Feuerstein ✡️ — I asked a $SLNO shareholder: WTF is going on?
Their reply: "PTSD from Sarepta"
🎯
August 2025 · 2 mentions
Aug 22
Adam Feuerstein ✡️ — $SLNO v @ScorpionFund update: Baird analyst @BrianSkorney spoke with Prader-Willi expert Dr. Ashley Shoemaker. https://t.co/Jjf4NISLIm↗
Aug 21
Adam Feuerstein ✡️ — My other story today: $SLNO vs @ScorpionFund
I spoke with CEO Anish Bhatnagar about Kir Kahlon's short report that claims Prader-Willi patients on Vykat XR are "dropping like fli…↗
Adam Feuerstein ✡️ — I can't remember the last time that a short seller factored so heavily in a biotech earnings call like this $SLNO call.
Maybe $MDXG back when Marc Cohodes was waging his war.…↗
Nov 4
Adam Feuerstein ✡️ — On call, $SLNO said Vykat discontinuation rate was 8% at end of Q3, and has been 10% overall.
"While the discontinuation rate has increased, it remains below our expected long te…↗
Adam Feuerstein ✡️ — @CoinbasedBTC I've been very bullish on $SLNO. Let's hope that continues.↗
Nov 4
Adam Feuerstein ✡️ — $SLNO earnings tonight. Consensus Vykat XR sales $54M, but buyside whisper is $60-70M.
Details on discontinuation rate also important.↗
Adam Feuerstein ✡️ — $SLNO under $50, cut in half since @ScorpionFund went public with his short thesis.
I still think Kir will be wrong fundamentally, but for now, he's most definitely winning. Hat.…↗